STALEVO 200
Stalevo 200 is a combination product containing levodopa, carbidopa, and entacapone. It is indicated for the treatment of patients with idiopathic Parkinson’s disease. It is primarily used to substitute for equivalent doses of its individual components or to replace carbidopa/levodopa therapy in patients who experience end-of-dose "wearing-off" (fluctuations in motor performance). The addition of entacapone to the carbidopa/levodopa regimen allows for more sustained plasma levels of levodopa, providing more consistent relief of motor symptoms such as bradykinesia and rigidity.
How STALEVO 200 Works
Parkinson’s disease symptoms result from dopamine depletion in the corpus striatum. Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier to replenish these levels. Carbidopa and Entacapone are included to optimize levodopa delivery. **Carbidopa** inhibits the peripheral decarboxylation of levodopa by aromatic amino acid decarboxylase. **Entacapone** is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting both decarboxylase and COMT enzymes, the peripheral metabolism of levodopa is significantly reduced. This leads to higher and more sustained serum levels of levodopa available for transport into the brain, effectively extending the duration of the clinical response and reducing "off" time.
Details
- Status
- Prescription
- First Approved
- 2003-06-11
- Routes
- ORAL
- Dosage Forms
- TABLET
STALEVO 200 Approval History
What STALEVO 200 Treats
5 indicationsSTALEVO 200 is approved for 5 conditions since its original approval in 2003. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Parkinson's Disease
- Post-Encephalitic Parkinsonism
- Symptomatic Parkinsonism
- Carbon Monoxide Intoxication
- Manganese Intoxication
Drugs Similar to STALEVO 200
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
STALEVO 200 FDA Label Details
ProIndications & Usage
FDA Label (PDF)Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidop...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.